He had no inside info... listen to the wording: "Just received word from a crony that MYDICAR will be rejected in april..." .. "rejected"? By whom? A phony through and trough. You can be right a lot of the time on these binary events, you know.
That was just conjecture based on your comment. What I'm reading, though, is that CUPID-1 had placebo, plus low, medium, and high doses, but only 39 patients.
Maybe they want to account for any risks of the procedure. It is an "intracoronary infusion" -- does not sound like a normal IV.
Genuinely interested here, not bashing. oakdesk58 says CUPID 1 was 88% risk reduction (and it seems to be), so why would you suggest that 7% is O.K., when CUPID 1 showed 88% and their target for CUPID 2 was 45%?
Are you buying any more at this price? Seems like one year's worth of gains have been wiped here, plus another 15%. (stock was at $14-16 this time last year)
I think what is going to stop it is a positive income. I am looking at the balance sheet and it's a disaster. No reported earnings info on the SEC website. No financial reports on their website. Not trying to bash, but this honestly looks like a scam to me. PLEASE tell me if there's some information I am missing.
Yes, pretty lazy. Cantor Fitzgerald did the same. They basically downgraded it to Thursday's AH close after fiddling with their projection numbers -- and voila, a day well $pent! They had something like a 35% yearly discount rate.
Since they are likely to change it to 25, that is going to be a "slam dunk".. I wonder if the share price would react.
"Rhopressa" (not Rophresa) definitely won't work for you. You're going to need maximum-strength timolol to be able to open your eyes... side effects be danged!
"ITS", for starters. You're welcome to keep posting nonsense. I will follow johngarcia's lead.
The 124m convertible debt is not a problem: it is a benefit. Without it, they would have to do secondaries at (currently) rock-bottom prices.
Do your own due diligence, but... helping you out here, it was not the day before, and wouldn't you sell some shares yourself if you had the equivalent of over $30M tied up in a binary outcome? This director lost over 11 million dollars in his remaining shares' market value on Thursday.
Yeah, the analysts often seem to sober up and cut their targets to basically what the thing is trading at...